You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

MASS. MOVERS

Amag results expected to come up short

ISTOCKPHOTO.COM

Continue reading below

Amag Pharmaceuticals Inc. slumped on preliminary fourth-quarter revenue of between $14.3 million and $15 million, lower than the $16 million analysts had estimated. The Lexington company put itself up for sale late last year after lackluster revenue for its anemia drug and a failed merger bid. It received approval for Feraheme from Canadian regulators in December. Amag said it expects fourth-quarter operating costs and expenses of $38 million to $43 million, including restructuring costs and a $2 million termination fee to Allos Therapeutics.

Loading comments...
Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking.
Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com